Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

BIDMC scientists identify new pathway to address the problem of photophobia during migraines

Ask anyone who suffers from migraine headaches what they do when they're having an attack, and you're likely to hear "go into a dark room." And although it's long been known that light makes migraines worse, the reason why has been unclear.

11 Jan 2010

Sciele Pharma announces the U.S. availability of Adrenaclick

Sciele Pharma, Inc., a Shionogi company, today announced the U.S. availability of Adrenaclick™, a single-dose, epinephrine auto-injector for the emergency treatment for severe allergic reactions (Type I) such as anaphylaxis.

8 Jan 2010

CCAC doubles its efforts to convince Canadians to prevent colorectal cancer

Following the results of the Angus Reid Strategies and the Applied Health Research Centre at Toronto's St. Michael's Hospital survey conducted on behalf of the Canadian Partnership Against Cancer finding that the majority of Canadians have a good understanding of the benefits of colorectal cancer screening, but are not taking action to get screened, the Colorectal Cancer Association of Canada ("CCAC") is doubling its efforts in 2010 to convince Canadians that they must be more proactive concerning their health and the onset of colorectal cancer.

7 Jan 2010

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose “Quad” regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.

7 Jan 2010

Texas Mutual Insurance offers tips to prevent H1N1 flu

Flu season peaks in January and February. For adults, the workplace is the most common place to catch the flu.

7 Jan 2010

CDC and AAFP recommend whooping cough vaccine for adults and adolescents

Many people may think of whooping cough as a disease of the past -- something eradicated generations ago. However, the number of cases reported by the Centers for Disease Control and Prevention (CDC) indicate that whooping cough (pertussis) is still very much a public health concern; health experts estimate that up to 600,000 cases occur each year in adults alone. In fact, whooping cough cases are on the rise in San Diego

6 Jan 2010

VELCADE sNDA receives FDA approval

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

5 Jan 2010

Health risks of wooden pallet shipping platforms, call for Congress and FDA regulation

The expanded recall of TYLENOL Arthritis pain reliever is fresh evidence of the need for Congress and the FDA to regulate wood pallets used to transport food and pharmaceuticals in the United States because of the dangers they pose to human health.

4 Jan 2010

Pfizer provides update on Prevnar 13

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the Biologics License Application (BLA) for Prevnar 13™, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s candidate 13-valent pneumococcal conjugate vaccine.

31 Dec 2009

Young people more likely to catch swine flu from an infected person in their household

Young people aged under 18 years are more likely than adults to catch swine flu from an infected person in their household, according to a new study published today in the New England Journal of Medicine.

30 Dec 2009

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis.

21 Dec 2009

Headache on rare occasions can be a warning sign of potentially serious disorder

Headaches are extremely common. Almost everyone has experienced a severe headache at least once in his or her lifetime. In most cases, headaches are minor nuisances that resolve within a short time. However, a headache can on rare occasions be the warning sign of a potentially serious disorder that requires immediate medical attention.

19 Dec 2009

Diabetes patients at higher risk from glaucoma

An estimated 3 million Americans have glaucoma, which can stealthily cause vision loss even before people realize they have the disease. People with diabetes face special risks from glaucoma. This January during Glaucoma Awareness Month, through its EyeSmart™ campaign, the American Academy of Ophthalmology in partnership with the American Glaucoma Society and the Glaucoma Research Foundation, remind Americans that knowing your glaucoma risks can save your sight and that people with diabetes need to be extra-vigilant.

19 Dec 2009

McNeil Consumer Healthcare announces recall of TYLENOL in bottles with red EZ-OPEN CAP

In consultation with the U.S. Food and Drug Administration (FDA), McNeil Consumer Healthcare, Division of McNEIL-PPC, Inc., is expanding its voluntary recall to include all available product lots of TYLENOL® Arthritis Pain Caplet 100 count bottles, with the distinctive red EZ-OPEN CAP (Full list of lot numbers provided below).

18 Dec 2009

GSK receives European CHMP positive opinion for Revolade

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

18 Dec 2009

BDSI's BEMA Buprenorphine Phase 2 study meets primary efficacy endpoint

BioDelivery Sciences International, Inc. announced that the primary efficacy endpoint was achieved in the Company’s Phase 2 pain study assessing the efficacy and safety of BEMA Buprenorphine. The positive results follow BDSI’s March 2009 announcement of favorable Phase 1 study results.

17 Dec 2009

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed headline results of the fourth and fifth of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence.

17 Dec 2009

FDA Advisory Committee votes against the approval of Tarceva

OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one recommending against approval of the daily pill Tarceva® (erlotinib) for first-line maintenance use in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has not progressed (grown or spread) following first-line treatment with platinum-based chemotherapy.

17 Dec 2009

New top-line results for patient preference study evaluating Kristalose for Oral Solution announced

Cumberland Pharmaceuticals Inc. (CPIX) today announced new top-line results for a patient preference study evaluating Kristalose (lactulose) for Oral Solution, a prescription laxative packaged as a crystalline powder, compared to similar products in liquid forms.

16 Dec 2009

Positive results from study comparing exenatide once weekly to BYETTA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to BYETTA® (exenatide) injection taken twice daily, in patients with type 2 diabetes.

15 Dec 2009

Vomiting News and Research

Further Reading

BIDMC scientists identify new pathway to address the problem of photophobia during migraines

Sciele Pharma announces the U.S. availability of Adrenaclick

CCAC doubles its efforts to convince Canadians to prevent colorectal cancer

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Texas Mutual Insurance offers tips to prevent H1N1 flu

CDC and AAFP recommend whooping cough vaccine for adults and adolescents

VELCADE sNDA receives FDA approval

Health risks of wooden pallet shipping platforms, call for Congress and FDA regulation

Pfizer provides update on Prevnar 13

Young people more likely to catch swine flu from an infected person in their household

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

Headache on rare occasions can be a warning sign of potentially serious disorder

Diabetes patients at higher risk from glaucoma

McNeil Consumer Healthcare announces recall of TYLENOL in bottles with red EZ-OPEN CAP

GSK receives European CHMP positive opinion for Revolade

BDSI's BEMA Buprenorphine Phase 2 study meets primary efficacy endpoint

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

FDA Advisory Committee votes against the approval of Tarceva

New top-line results for patient preference study evaluating Kristalose for Oral Solution announced

Positive results from study comparing exenatide once weekly to BYETTA

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News